Xenetic Biosciences Q2 2025 Earnings Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress INMD Q1 2026 Earnings EPS Misses Estimates by 1744 Amid Challenging Quarter XRX Q1 2026 Earnings EPS Misses Estimates Amid Restructuring Stock Rises 98 BFRI Q1 2026 Earnings Wide EPS Miss Fails to Dampen Investor Sentiment OPRT Q1 2026 Earnings EPS Surpasses Estimates by 243 Despite Stock Decline AREC Q4 2025 Earnings Massive EPS Surprise of 1008 Beats Estimates